aspirin and xv 459

aspirin has been researched along with xv 459 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cain, VA; Ebling, W; Fossler, MJ; Kornhauser, DM; Ma, S; Mondick, JT; Pieniaszek, HJ; Sy, SK	1

Trials

1 trial(s) available for aspirin and xv 459

Article	Year
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. Journal of clinical pharmacology, 2002, Volume: 42, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Amidines; Amino Acids; Area Under Curve; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Hydrolysis; Isoxazoles; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Time Factors	2002

Article

Year

Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.

Journal of clinical pharmacology, 2002, Volume: 42, Issue:7

Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Amidines; Amino Acids; Area Under Curve; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Hydrolysis; Isoxazoles; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Time Factors

2002